ELSEVIER

Journal of Affective Disorders 62 (2001) 243–244

JOURNAL OF AFFECTIVE DISORDERS

www.elsevier.com/locate/jad

Author index

Ackenheil, M.
Neurotransmitters and signal transduction processes in bipolar affective disorders: a synopsis (62) 101
Agelink, M.W., Majewski, T., Wurthmann, C., Postert, T., Linka, T., Rotterdam, S. and Klieser, E.
Autonomic neurocardiac function in patients with major depression and effects of antidepressive treatment with nefazodone (62) 187
Akiskal, H.S., Katona, C.
The field of affective disorders a centuary after Kraepelin (62) 1
Akiskal, H.S.
Dysthymia and cyclothymia in psychiatric practice a century after Kraepelin (62) 17
Andrew, J.E., Wileman, S.M., Howie, F.L., Cameron, I.M., Naji, S.A. and Eagles, J.M.
Comparison of consultation rates in primary care attenders with and without seasonal affective disorder (62) 199
Angst, J. and Merikangas, K.R.
Multi-dimensional criteria for the diagnosis of depression (62) 7

Barbini, B., see Benedetti, F. (62) 221
Belmaker, R.H., see Einat, H. (62) 113
Benedetti, F., Colombo, C., Barbini, B., Campori, E. and Smeraldi, E.
Morning sunlight reduces length of hospitalization in bipolar depression (62) 221
Berman, J., see Sarchiapone, M. (62) 217

Camardese, G., see Sarchiapone, M. (62) 217
Cameron, I.M., see Andrew, J.E. (62) 199
Campori, E., see Benedetti, F. (62) 221
Colombo, C., see Benedetti, F. (62) 221

Dalgleish, T., see Spinks, H. (62) 229
De, T., see Shah, A. (62) 233
Della Casa, S., see Sarchiapone, M. (62) 217
De Risio, S., see Sarchiapone, M. (62) 217

Eagles, J.M., see Andrew, J.E. (62) 199
Einat, H. and Belmaker, R.H.
The effects of inositol treatment in animal models of psychiatric disorders (62) 113
Engvik, H., see Lingjærde, O. (62) 165
Erazo, N., see Greil, W. (62) 225

Fombonne, E., see Simic, M. (62) 175
Føreland, A.R., see Lingjærde, O. (62) 165
Frank, E., see Kupfer, D.J. (62) 131
Fritzsche, M., Heller, R., Hill, H. and Kick, H.
Sleep deprivation as a predictor of response to light therapy in major depression (62) 207

Gallinat, J., see Hegerl, U. (62) 93
Gonzalez, B., see Sarchiapone, M. (62) 217
Greil, W., Horvath, A., Sassim, N., Erazo, N. and Grohmann, R.
Disinhibition of libido: an adverse effect of SSRI? (62) 225
Grohmann, R., see Greil, W. (62) 225

Hegerl, U., Gallinat, J. and Juckel, G.
Event-related potentials. Do they reflect central serotonergic neurotransmission and do they predict clinical response to serotonin agonists? (62) 93
Heller, R., see Fritzsche, M. (62) 207
Hill, H., see Fritzsche, M. (62) 207
Hippius, H., see Möller, H.-J. (62) 3
Holsboer, F.
Stress, hypercortisolism and corticosteroid receptors in depression: implicatons for therapy (62) 77
Holsboer, F., see Krieg, J.-C. (62) 33
Horvath, A., see Greil, W. (62) 225
Howie, F.L., see Andrew, J.E. (62) 199

Juckel, G., see Hegerl, U. (62) 93

Kato, N., see Kato, T. (62) 151
Kato, T., Kunugi, H., Nanko, S. and Kato, N.
Mitochondrial DNA polymorphisms in bipolar disorder (62) 151
Katona, C., see Akiskal, H.S. (62) 1
Katona, C., see Thompson, C. (62) 139
Kick, H., see Fritzsche, M. (62) 207
Klieser, E., see Agelink, M.W. (62) 187
Krieg, J.-C., Lauer, C.J., Schreiber, W., Modell, S. and Holsboer, F.
Neuroendocrine, polysomnographic and psychometric observations in healthy subjects at high familial risk for affective

S0165-0327(01)00319-6

disorders: the current state of the 'Munich vulnerability study' (62) 33
Kunugi, H., see Kato, T. (62) 151
Kupfer, D.J. and Frank, E.
The interaction of drug- and psychotherapy in the long-term treatment of depression (62) 131

Lauer, C.J., see Krieg, J.-C. (62) 33
Lesch, K.P.
Serotonergic gene expression and depression: implications for developing novel antidepressants (62) 57
Lingjærde, O., Føreland, A.R. and Engvik, H.
Personality structure in patients with winter depression, assessed in a depression-free state according to the five-factor model of personality (62) 165
Linka, T., see Agelink, M.W. (62) 187

Majewski, T., see Agelink, M.W. (62) 187
Marneros, A.
Expanding the group of bipolar disorders (62) 39
Mendlewicz, J., see Souery, D. (62) 45
Merikangas, K.R., see Angst, J. (62) 7
Modell, S., see Krieg, J.-C. (62) 33
Möller, H.-J., Müller, N. and Hippius, H.
Molecular and clinical aspects of affective disorders–a hundred years after the Kraepelinian concept of manic-depressive psychosis (62) 3
Müller, N., see Möller, H.-J. (62) 3

Naji, S.A., see Andrew, J.E. (62) 199
Nanko, S., see Kato, T. (62) 151

Odutoye, K., see Shah, A. (62) 233

Paykel, E.S.
The evolution of life events research in psychiatry (62) 141
Postert, T., see Agelink, M.W. (62) 187

Rivelli, S.K., see Souery, D. (62) 45
Rotterdam, S., see Agelink, M.W. (62) 187
Roy, A., see Sarchiapone, M. (62) 217
Rutz, W.
Preventing suicide and premature death by education and treatment (62) 123

Sarchiapone, M., Camardese, G., Roy, A., Della Casa, S., Satta, M.A., Gonzalez, B., Berman, J. and De Risio, S.
Cholesterol and serotonin indices in depressed and suicidal patients (62) 217
Sassim, N., see Greil, W. (62) 225
Satta, M.A., see Sarchiapone, M. (62) 217
Schreiber, W., see Krieg, J.-C. (62) 33
Shah, A., Odutoye, K. and De, T.
Depression in acutely medically ill elderly inpatients: a pilot study of early identification and intervention by formal psychogeriatric consultation (62) 233
Simic, M. and Fombonne, E.
Depressive conduct disorder: symptom patterns and correlates in referred children and adolescents (62) 175
Smeraldi, E., see Benedetti, F. (62) 221
Souery, D., Rivelli, S.K. and Mendlewicz, J.
Molecular genetic and family studies in affective disorders: state of the art (62) 45
Spinks, H. and Dalgleish, T.
Attentional processing and levels of symptomatology in Seasonal Affective Disorder (SAD): a preliminary longitudinal study (62) 229

Thompson, C. and Katona, C.
The journal welcomes its new partnerships with the International Society for Affective Disorders (ISAD) and the WPA Section of Affected Disorders (62) 139

Wileman, S.M., see Andrew, J.E. (62) 199
Wurthmann, C., see Agelink, M.W. (62) 187

ELSEVIER

Journal of Affective Disorders 62 (2001) 245–247

JOURNAL OF AFFECTIVE DISORDERS

www.elsevier.com/locate/jad

Subject index

Adolescents; Depression; Conduct disorder; Comorbidity; Children **62,** 175

Animal models; Inositol; Depression; Anxiety; Second messengers **62,** 113

Anticipation; Molecular genetics; Bipolar affective disorders; DNA markers; Dynamic mutations **62,** 45

Antidepressant drugs; Serotonin; Depression; Gene **62,** 57

Antidepressants; Stress; Depression; HPA system; Corticotropin-releasing hormone **62,** 77

Antidepressants side-effects; Major depression; Nefazodone; Autonomic nervous system; Heart rate variability; Mortality; Cardiovascular **62,** 187

Anxiety; Inositol; Animal models; Depression; Second messengers **62,** 113

Autonomic nervous system; Major depression; Antidepressants side-effects; Nefazodone; Heart rate variability; Mortality; Cardiovascular **62,** 187

Bipolar affective disorders; Molecular genetics; DNA markers; Anticipation; Dynamic mutations **62,** 45

Bipolar affective disorders; Neurotransmitters; Signal transduction processes **62,** 101

Bipolar depression; Sunlight; Hospitalization **62,** 221

Bipolar disorder; Mania, Schizoaffective; Unipolar **62,** 39

Bipolar disorder; Genetics; Mitochondrial DNA; Risk factors **62,** 151

Cardiovascular; Major depression; Antidepressants side-effects; Nefazodone; Autonomic nervous system; Heart rate variability; Mortality **62,** 187

Children; Depression; Conduct disorder; Comorbidity; Adolescents **62,** 175

Cholesterol; Depression; Suicide; *d*-Fenfluramine; Serotonin **62,** 217

Combination treatment; Recurrence; Long-term treatment **62,** 131

Comorbidity; Depression; Conduct disorder; Children; Adolescents **62,** 175

Conduct disorder; Depression; Comorbidity; Children; Adolescents **62,** 175

Consultations; Seasonality; Seasonal affective disorder; Primary care **62,** 199

Corticotropin-releasing hormone; Stress; Depression; HPA system; Antidepressants **62,** 77

Criteria; Depression; Subtypes; Subthreshold; Epidemiology **62,** 7

Cyclothynmia; Kraepelin; Temperament; Dysthymia; Subthreshold mood disorders; Prevention **62,** 17

Depression; Subtypes; Criteria; Subthreshold; Epidemiology **62,** 7

Depression; Vulnerability Markers; Neuroendocrinology; Polysomnography; Psychometrics **62,** 33

Depression; Serotonin; Gene; Antidepressant drugs **62,** 57

Depression; Stress; HPA system; Corticotropin-releasing hormone; Antidepressants **62,** 77

Depression; Inositol; Animal models; Anxiety; Second messengers **62,** 113

Depression; Conduct disorder; Comorbidity; Children; Adolescents **62,** 175

Depression; Suicide; Cholesterol; *d*-Fenfluramine; Serotonin **62,** 217

Depression; Elderly; Medical illness; Intervention **62,** 233

Depressive disorder; Drug surveillance; Selective serotonin reuptake inhibitor; Psychic adverse drug reaction; Increased libido; Mixed states **62,** 225

DNA markers; Molecular genetics; Bipolar affective disorders; Anticipation; Dynamic mutations **62,** 45

Drug surveillance; Depressive disorder; Selective serotonin reuptake inhibitor; Psychic adverse drug reaction; Increased libido; Mixed states **62,** 225

Dynamic mutations; Molecular genetics; Bipolar affective disorders; DNA markers; Anticipation **62,** 45

Dysthymia; Kraepelin; Temperament; Cyclothynmia; Subthreshold mood disorders; Prevention **62,** 17

S0165-0327(01)00320-2

Education; Suicide prevention; Premature death; Treatment **62,** 123

Elderly; Depression; Medical illness; Intervention **62,** 233

Epidemiology; Depression; Subtypes; Criteria; Subthreshold **62,** 7

Event-related potentials; Serotonin; SSRI; Lithium **62,** 93

***d-Fenfluramine*;** Depression; Suicide; Cholesterol; Serotonin **62,** 217

Gene; Serotonin; Depression; Antidepressant drugs **62,** 57

Genetics; Bipolar disorder; Mitochondrial DNA; Risk factors **62,** 151

Heart rate variability; Major depression; Antidepressants side-effects; Nefazodone; Autonomic nervous system; Mortality; Cardiovascular **62,** 187

Hospitalization; Sunlight; Bipolar depression **62,** 221

HPA system; Stress; Depression; Corticotropin-releasing hormone; Antidepressants **62,** 77

Increased libido; Depressive disorder; Drug surveillance; Selective serotonin reuptake inhibitor; Psychic adverse drug reaction; Mixed states **62,** 225

Information processing; Stroop; SAD **62,** 229

Inositol; Animal models; Depression; Anxiety; Second messengers **62,** 113

Intervention; Depression; Elderly; Medical illness **62,** 233

Kraepelin; Temperament; Dysthymia; Cyclothynmia; Subthreshold mood disorders; Prevention **62,** 17

Lithium; Event-related potentials; Serotonin; SSRI **62,** 93

Long-term treatment; Recurrence; Combination treatment **62,** 131

Major depression; Antidepressants side-effects; Nefazodone; Autonomic nervous system; Heart rate variability; Mortality; Cardiovascular **62,** 187

Major depression; Light therapy; Sleep deprivation; Treatment outcome **62,** 207

Mania, Schizoaffective; Bipolar disorder; Unipolar **62,** 39

Medical illness; Depression; Elderly; Intervention **62,** 233

Mitochondrial DNA; Bipolar disorder; Genetics; Risk factors **62,** 151

Mixed states; Depressive disorder; Drug surveillance; Selective serotonin reuptake inhibitor; Psychic adverse drug reaction; Increased libido **62,** 225

Molecular genetics; Bipolar affective disorders; DNA markers; Anticipation; Dynamic mutations **62,** 45

Mortality; Major depression; Antidepressants side-effects; Nefazodone; Autonomic nervous system; Heart rate variability; Cardiovascular **62,** 187

Nefazodone; Major depression; Antidepressants side-effects; Autonomic nervous system; Heart rate variability; Mortality; Cardiovascular **62,** 187

Neuroendocrinology; Depression; Vulnerability Markers; Polysomnography; Psychometrics **62,** 33

Neurotransmitters; Signal transduction processes; Bipolar affective disorders **62,** 101

Personality; Seasonal Affective Disorder; Winter depression **62,** 165

Polysomnography; Depression; Vulnerability Markers; Neuroendocrinology; Psychometrics **62,** 33

Premature death; Suicide prevention; Education; Treatment **62,** 123

Prevention; Kraepelin; Temperament; Dysthymia; Cyclothynmia; Subthreshold mood disorders **62,** 17

Primary care; Seasonality; Seasonal affective disorder; Consultations **62,** 199

Psychic adverse drug reaction; Depressive disorder; Drug surveillance; Selective serotonin reuptake inhibitor; Increased libido; Mixed states **62,** 225

Psychometrics; Depression; Vulnerability Markers; Neuroendocrinology; Polysomnography **62,** 33

Recurrence; Long-term treatment; Combination treatment **62,** 131

Risk factors; Bipolar disorder; Genetics; Mitochondrial DNA **62,** 151

SAD; Stroop; Information processing **62,** 229

Seasonal Affective Disorder; Personality; Winter depression **62,** 165

Seasonal affective disorder; Seasonality; Consultations; Primary care **62,** 199

Seasonality; Seasonal affective disorder; Consultations; Primary care **62,** 199

Second messengers; Inositol; Animal models; Depression; Anxiety **62,** 113

Selective serotonin reuptake inhibitor; Depressive disorder; Drug surveillance; Psychic adverse drug reaction; Increased libido; Mixed states **62,** 225

Serotonin; Depression; Gene; Antidepressant drugs **62,** 57

Sertonin; Event-related potentials; SSRI; Lithium **62,** 93

Serotonin; Depression; Suicide; Cholesterol; *d*-Fenfluramine **62,** 217

Signal transduction processes; Neurotransmitters; Bipolar affective disorders **62,** 101

Sleep deprivation; Major depression; Light therapy; Treatment outcome **62,** 207

SSRI; Event-related potentials; Serotonin; Lithium **62,** 93

Stress; Depression; HPA system; Corticotropin-releasing hormone; Antidepressants **62,** 77

Stroop; SAD; Information processing **62,** 229

Subthreshold; Depression; Subtypes; Criteria; Epidemiology **62,** 7

Subthreshold mood disorders; Kraepelin; Temperament; Dysthymia; Cyclothynmia; Prevention **62,** 17

Subtypes; Depression; Criteria; Subthreshold; Epidemiology **62,** 7

Suicide; Depression; Cholesterol; *d*-Fenfluramine; Serotonin **62,** 217

Suicide prevention; Premature death; Education; Treatment **62,** 123

Sunlight; Bipolar depression; Hospitalization **62,** 221

Temperament; Kraepelin; Dysthymia; Cyclothynmia; Subthreshold mood disorders; Prevention **62,** 17

Treatment; Suicide prevention; Premature death; Education **62,** 123

Treatment outcome; Major depression; Light therapy; Sleep deprivation **62,** 207

Unipolar; Bipolar disorder; Mania, Schizoaffective **62,** 39

Vulnerability Markers; Depression; Neuroendocrinology; Polysomnography; Psychometrics **62,** 33

Winter depression; Personality; Seasonal Affective Disorder **62,** 165